Potassium Bicarbonate
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Potassium Bicarbonate: From Peptic Ulcer Disease to Gastroduodenitis
One-Sentence Summary
Potassium bicarbonate is an alkalinizing agent and potassium source, originally used for conditions such as potassium deficiency and acid-related upper gastrointestinal disorders (peptic ulcer disease, GERD, esophagitis, dyspepsia). The TxGNN model predicts it may be effective for gastroduodenitis, but currently there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Peptic ulcer disease, potassium deficiency disease, gastroesophageal reflux disease, esophagitis, peptic esophagitis, dyspepsia (from the knowledge graph; the US product record lists no approved indication text) |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 99.72% |
| Evidence Level | L5 |
| US Market Status | Cancelled only |
| Number of NDAs | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, potassium bicarbonate is an alkalinizing agent and a potassium source. Its listed original indications include several upper gastrointestinal acid-related conditions, and mechanistically it may be applicable to gastroduodenitis.
Gastroduodenitis (inflammation of the stomach and duodenum) is closely related to peptic ulcer disease, GERD, esophagitis and dyspepsia. A plausible explanation is gastric acid neutralization. However, this is an inference by analogy and has not been verified by any trial or publication.
Because the predicted indication sits so close to the existing indications, it may represent an extension of the existing use rather than a true repurposing. No route-compatibility assessment is available; the only known formulation is an oral effervescent tablet.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Not available | Effer-K (Nomax Inc.) | Effervescent tablet (oral) | Not available |
The only authorization on record is cancelled; there are no currently valid single-ingredient or combination authorizations.
Safety Considerations
- Contraindications suggested by the knowledge graph (disease associations, not package insert text): congestive heart failure, anuria, atrioventricular block, hyperkalemic periodic paralysis, periodic paralysis, hypoaldosteronism, myotonia congenita. These are consistent with the risk of raising potassium levels.
- Drug Interactions: 59 interactions were identified. Of the 20 listed, the main ones are:
- Major: ACE inhibitors (fosinopril, benazepril, captopril, enalapril), angiotensin receptor blockers (olmesartan, valsartan, azilsartan medoxomil, eprosartan), potassium-sparing diuretics and aldosterone antagonists (amiloride, spironolactone, eplerenone). These combinations can raise the risk of hyperkalemia.
- Moderate: NSAIDs (ketorolac, ibuprofen, diclofenac, oxaprozin, bromfenac, diflunisal, etodolac), aliskiren, and drospirenone.
Please refer to the package insert for further safety information, such as warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score (99.72%) but no supporting clinical trials or literature (evidence level L5). The US product is cancelled, there is no mechanism data, and the many interactions with hyperkalemia-related drugs need careful review.
To proceed, the following is needed:
- Package insert warnings and contraindications (currently a blocking gap for safety screening)
- Detailed mechanism of action data (MOA)
- Literature and trial searches for potassium bicarbonate or alkalinizing agents in gastroduodenitis
- Assessment of whether gastroduodenitis is a true new indication or an extension of existing uses
- Review of the cancelled market status and the hyperkalemia-related interaction risk
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.